{
    "clinical_study": {
        "@rank": "13173", 
        "acronym": "EGFRI", 
        "arm_group": [
            {
                "arm_group_label": "RECONVAL CREAM", 
                "arm_group_type": "Experimental", 
                "description": "half face treated with RECONVAL CREAM"
            }, 
            {
                "arm_group_label": "PLACEBO", 
                "arm_group_type": "Placebo Comparator", 
                "description": "half face treated with PLACEBO cream"
            }
        ], 
        "brief_summary": {
            "textblock": "Vitamin K1 cream may prevent papulopustular rash induced by EGFRI given to metastatic\n      colorectal cancer patients.\n\n      This study will prospectively accrue metastatic colorectal patients receiving EGFRI and\n      treat with reconval cream half face versus placebo cream half face to study whether Vitamin\n      k1 cream can prevent the typical skin eruption caused by EGFRI."
        }, 
        "brief_title": "A Study to Examine the Effect of Reconval K1 Cream to Prevent Skin Toxicity From EGFRI", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Rash Due to Epidermal Growth Factor Receptor Inhibitors", 
        "condition_browse": {
            "mesh_term": "Exanthema"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  metastatic colon cancer patients\n\n          -  male or female\n\n          -  age> 18\n\n          -  treated EGFRI\n\n        Exclusion Criteria:\n\n          -  prior treatment  with EGFRI"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01763307", 
            "org_study_id": "EGFRI-MER-1a-HMO-CTIL"
        }, 
        "intervention": [
            {
                "arm_group_label": "RECONVAL CREAM", 
                "intervention_name": "RECONVAL CREAM", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "PLACEBO", 
                "intervention_name": "PLACEBO", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "EGFRI", 
            "COLON CANCER", 
            "SKIN TOXICITY", 
            "RECONVAL K1 cream"
        ], 
        "lastchanged_date": "January 7, 2013", 
        "number_of_arms": "2", 
        "official_title": "A Phase II Randomized, Double Blind, Placebo Study to Evaluate the Efficacy of Vitamin K1 Cream Treatment Compared to Placebo for the Prevention of Papulo-pustular Rash in Metastatic Colorectal Patients Receiving First Line EGFRI Treatment.", 
        "overall_contact": {
            "email": "lhadas@hadassah.org.il", 
            "last_name": "Hadas` Lemberg, PHD LLB", 
            "phone": "+972 2 6776095"
        }, 
        "overall_official": {
            "affiliation": "Hadassah Medcial Organization", 
            "last_name": "Sharon Merims, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Israeli Health Ministry Pharmaceutical Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Reduction in numbers of papulo-pustular eruptions in the treatment fields compared to the placebo treated side. Changes in follicular eruptions, dryness/redness of skin estimated by the grading scale developed by the Multinational Association of Supportive Care in Cancer (MASCC) skin toxicity study group  4.0. Patients own experience of efficacy estimated by questionnaire.", 
            "measure": "Potential reduction in skin toxicity by Vitamin K1 cream in metastatic colorectal patients treated with EGFRI", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01763307"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Hadassah Medical Organization", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hadassah Medical Organization", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}